Skip To Main Content
Mohamed-Reda Benmebarek on Muck Rack

Mohamed-Reda Benmebarek

As seen in: Nature, Science Magazine, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mohamed-Reda

Contact Mohamed-Reda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases - Nature Communications

|
By Xin Wang, Martin Arhin, Shadin Ghabra, Francisco Rodriguez-Matos, Mohamed-Reda Benmebarek, Chi Ma, Firouzeh Korangy, Dillon Strepay
| Nature Verified
Abstract Functional tumor-specific CD8+ T cells are essential for effective anti-tumor immune response and immune checkpoint inhibitor therapy. Here we show that, compared to other organ sites, primary, metastatic liver tumors in murine models contain a higher number of tumor-specific CD8+ T cells which are also dysfunctional.
Open in Who Shared Issue with article?

Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME

|
By Mohamed-Reda Benmebarek, Cihan Oguz, Matthias Seifert, Benjamin Ruf, Yuta Myojin, Kylynda C. Bauer, Patrick Huang, Chi Ma, Marina Villamor-Payà, Francisco Rodriguez-Matos, Marlaine Soliman, Rajiv S. Trehan, Cecilia Monge, Changqing Xie, David E Kleiner, Bradford J. Wood, Elliot B. Levy, Anuradha Budhu, Noemi Kedei, Christian Mayer, Xin Wang, Justin B Lack, William Telford Verified, Firouzeh Korangy, Tim F. Greten
| Cell Press Verified
Keywords cholangiocarcinoma CCA immune checkpoint blockade ICB tumor microenvironment TME tertiary lymphoid structures TLSs BAFF regulatory T cells Tregs Treg fragility Get full text access Log in, subscribe or purchase for full access. References 1. Greten, T.F. ∙ Schwabe, R. ∙ Bardeesy, N. ... Immunology and immunotherapy of cholangiocarcinoma Nat. Rev. Gastroenterol. Hepatol. 2023; 20:349-365 2. Kitano, Y. ∙ Okabe, H. ∙ Yamashita, Y.I. ...
Open in Who Shared Issue with article?

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

|
By Bruno L. Cadilha, Mohamed-Reda Benmebarek, Klara Dorman, Arman Oner
| Science Magazine Verified
Abstract CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response via inhibitory factors such as transforming growth factor–β (TGF-β). Treg cells expressing the C-C chemokine receptor 8 (CCR8) have been associated with poor prognosis in solid tumors.
Open in Who Shared Issue with article?
See all 4 articles